Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 491.86% and ...

Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

The rising price of insulin has become one of the most talked about issues across the pharma industry. Ben Hargreaves explains how Eli Lilly decided to cap its insulin price, why it has decided to ...

MADISON, Wisconsin: Eli Lilly is doubling down on manufacturing investments, announcing a US$3 billion expansion of its Wisconsin facility to meet growing demand for its blockbuster diabetes and ...

Those at risk include people living with type 2 diabetes or high blood pr Eli Lilly and Company (NYSE: LLY) today announced a $3 billion expansion of the Kenosha County, Wisconsin, manufacturing ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Eli Lilly is doubling down on manufacturing investments, announcing a US$3 billion expansion of its Wisconsin facility This will meet the growing demand for its blockbuster diabetes and obesity drugs, ...

India's pharmaceutical retail market rebounded in November with double-digit growth, driven by increased demand for ...

Dec. 6, 2024 — Scientists have unveiled a novel compound, HPH-15, with dual effects of reducing blood glucose levels and combating fat accumulation, marking a significant leap in diabetes treatment ...